Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study

Uittenboogaard, Aniek; Velde, Mirjam van de; Heijden, Lisa van de; Mukuhi, Leah; Vries, Niels de; Langat, Sandra; Olbara, Gilbert; Huitema, Alwin D. R; Vik, Terry; Kaspers, Gertjan; Njuguna, Festus

dc.contributor.author	Uittenboogaard, Aniek
dc.contributor.author	Velde, Mirjam van de
dc.contributor.author	Heijden, Lisa van de
dc.contributor.author	Mukuhi, Leah
dc.contributor.author	Vries, Niels de
dc.contributor.author	Langat, Sandra
dc.contributor.author	Olbara, Gilbert
dc.contributor.author	Huitema, Alwin D. R
dc.contributor.author	Vik, Terry
dc.contributor.author	Kaspers, Gertjan
dc.contributor.author	Njuguna, Festus
dc.date.accessioned	2025-02-20T08:54:42Z
dc.date.available	2025-02-20T08:54:42Z
dc.date.issued	2024-06-10
dc.identifier.uri	http://ir.mu.ac.ke:8080/jspui/handle/123456789/9550
dc.description.abstract	The low incidence of vincristine-induced peripheral neuropathy (VIPN) in Kenyan children may result from low vincristine exposure. We studied vincristine expo- sure in Kenyan children and dose-escalated in case of low vincristine exposure (NCT05844670). Average vincristine exposure was high. Individual vincristine expo- sure was assessed with a previously developed nomogram. A 20% dose increase was recommended for participants with low exposure and no VIPN, hyperbilirubinemia, or malnutrition. None of the 15 participants developed VIPN. Low vincristine exposure was seen in one participant: a dose increase was implemented without side effects. In conclusion, the participants did not develop VIPN despite having high vincristine exposure.	en_US
dc.language.iso	en	en_US
dc.publisher	Wiley	en_US
dc.subject	Individualized dosing,	en_US
dc.subject	Pediatric oncology	en_US
dc.subject	Pharmacokinetics	en_US
dc.subject	Vincristine	en_US
dc.title	Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study	en_US
dc.type	Article	en_US